Navigation Links
Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
Date:7/23/2012

CAMBRIDGE, Mass., July 23, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

Having completed enrollment of a 150-patient randomized Phase 2 study in advanced non-small cell lung cancer, Cerulean is beginning to capitalize on the breadth of the CRLX101 opportunity by expanding its development into additional tumor types with several studies conducted by leading investigators.  This newly opened trial is designed to evaluate the activity of CRLX101, a nanopharmaceutical that inhibits both topoisomerase 1 and hypoxia-inducible factor-1 alpha, in ovarian cancer patients whose disease has progressed following standard first-line platinum-based therapy.  Current approved second-line therapy for ovarian cancer includes use of the topoisomerase 1 inhibitor, topotecan, which has limitations.  The study is being conducted at the Massachusetts General Hospital and led by principal investigator Carolyn Krasner, M.D., in cooperation with the Dana Farber Cancer Institute, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center.  

"Not only do women with advanced stage ovarian cancer have limited treatment options, but they also suffer from many disease-related symptoms and treatment-related side effects," said Dr. Krasner.  "This study will enable us to evaluate the potential use of CRLX101 as a treatment option for those patients." 

"This trial is intended to build on our current clinical data and determine if CRLX101 can offer ovarian cancer patients a new treatment option," said Edward Garmey, M.D., chief medical officer of Cerulean.  "We are excited to partner with Dr. Krasner and to expand the development strategy of CRLX101 in an indication w
'/>"/>

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
2. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
3. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
4. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
5. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. China Health Resource Announces Go Global Initiative For New Product Introductions
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
9. Ampio Pharmaceuticals Announces Closing of Public Offering
10. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
11. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  In 2008, two of Dr. Gurney,s employees reported ... substances, on a regular basis, that were not used ... was practicing "all the time" while under the influence. ... said that Dr. Gurney was prone to "making mistakes ... Dr. Gurney,s behavior became increasingly erratic and unfocused, and ...
(Date:10/25/2014)... , Oct. 24, 2014 In conjunction ... quarter 2014 financial results press release, you are invited ... broadcast live over the internet on Monday, November 3, ... Time). A live audio webcast of the ... http://www.durect.com and clicking "Investor Relations."  If you ...
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research Institute, ... Drug Administration (FDA) has given the company permission to ... in patients > 3 months of age with a ... placed in one of five treatment groups based on ... prior treatment for DIPG. The primary study endpoint is ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 ... biology, today announced Dr. Xun Wang ... all Research & Development. , Triton has developed a ... value algae-based proteins. According to Dr. Wang, the platform ... traditional expression systems. He says, “Algae are unique because ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The global ... CAGR of 7.6%, to reach $50.4 billion by 2018 ... healthcare systems industry, and pharmaceutical industry are driving the ... model to enhance their focus on core business, reduce ... and trained staff (further reducing hiring and training costs), ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the Connecticut ... the field of establishing recovery community organizations. Bob had ... he retired, he set out to answer a couple questions ... , 1. Where are the people in recovery when ... Can the recovery community be organized to advocate for issues ...
(Date:10/25/2014)... 2014 Market Research Report ... 2009-2019 is a professional and in-depth market ... industry. The report firstly reviews the basic ... application and manufacturing technology. The report then ... Molecular Diagnostics listing their product specification, capacity, ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
Breaking Medicine News(10 mins):Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4
... Resources, an,association management and consulting firm for non-profit organizations,located ... launch of an,innovative e-learning solution to be used by ... of the service will offer a way to,increase revenue ... , "We,re excited about this ...
... CORTLANDT MANOR, N.Y., Feb. 3 Polymedco is pleased to ... and screening. It is designed to educate both patients ... cancer. The website is located at www.fobt-tests.com . ... cancer related death today in the United States. However, ...
... of change echoing across the country, Americans have been ... greatness of this nation. America,s ability to seize this ... by each individual. In celebration of the inherent excellence ... forum in which everyday stories of greatness will be ...
... Aldridge LLP (MLA) is pleased to announce that Paul ... has joined the firm in our Government Contracts Department. ... firm,s Life Sciences and Public Health Preparedness practice in ... addition to helping clients develop strategies for offering their ...
... Mich., Feb. 3 Cherries are not only good for ... According to recent,data, more than 9 out of 10 Americans ... say they,re purchasing "locally produced" products,and the majority are defining ... About ninety-five percent of cherries consumed in ...
... 3 To mark American Heart,Month, deCODE genetics (Nasdaq: ... of,February it will offer its deCODEme Cardio Scan(TM), the ... inherited risk of heart,attack, stroke and atrial fibrillation, intracranial ... promotional price of,$100. , On ...
Cached Medicine News:Health News:Center for Association Resources Launches E-Learning Service 2Health News:Nature Made(R) Seeking Stories of Individual Greatness for Upcoming Documentary 2Health News:Nature Made(R) Seeking Stories of Individual Greatness for Upcoming Documentary 3Health News:Former Assistant Secretary of Defense for Homeland Defense Joins McKenna Long & Aldridge LLP 2Health News:Cherries: 'America's Super Fruit' Offers Homegrown Health Benefits 2Health News:Cherries: 'America's Super Fruit' Offers Homegrown Health Benefits 3Health News:deCODEme(TM) Takes on Heart Disease in February 2Health News:deCODEme(TM) Takes on Heart Disease in February 3Health News:deCODEme(TM) Takes on Heart Disease in February 4Health News:deCODEme(TM) Takes on Heart Disease in February 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: